 NOVATO, Calif., Jan. 06, 2022 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the companys Chief Executive Officer and President, will present at the H.C. Wainwright BioConnect Conference on Thursday, January 13, 2022 at 7:00 AM ET. 